This content is machine translated Psoriasis Research: What's in the Pipeline? Highly selective oral TYK inhibitors in Phase III Envudeucitinib and Zasocitinib are oral, allosteric tyrosine kinase 2 (TYK2) inhibitors currently being evaluated in clinical trials for plaque psoriasis. The interim results presented during the Late-Breaking Research sessions at...…
